FX-1610

FX-1610 is a preclinical small molecule inhibitor of the DYRK1 kinase family, developed by Felicitex Therapeutics. The compound is specifically designed to target dormant cancer cells, which are often responsible for treatment resistance, metastasis, and disease recurrence. By selectively disrupting the dormancy state, FX-1610 forces cancer cells into a vulnerable state where they accumulate DNA damage and undergo apoptosis. Felicitex is positioning FX-1610 for the treatment of various cancers, with a primary focus on pediatric acute leukemia and other hematopoietic malignancies. The drug was undergoing IND-enabling studies with plans for clinical entry in 2023.